Substance / Medication

Estramustine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.

Lubiniecki Gregory M, Berlin Jesse A, Weinstein Rachel B et al. · Cancer · 2004

PMID: 15536625Meta-Analysis

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Hirano Daisaku, Nagane Yusuke, Satoh Katsuhiko et al. · Int Urol Nephrol · 2010

PMID: 19449118RCT

Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.

Kitamura T, Suzuki M, Nishimatsu H et al. · Aktuelle Urol · 2010

PMID: 20094950Observational

A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.

Hoshi Senji, Yamaguchi Osamu, Fujioka Tomoaki et al. · Int J Clin Oncol · 2006

PMID: 16937304Observational

Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.

Hirano Daisaku, Minei Sadatsugu, Kishimoto Yuichi et al. · Urol Int · 2005

PMID: 16037707Observational

Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.

Oudard Stephane, Legrier Marie-Emmanuelle, Boyé Karine et al. · J Urol · 2003

PMID: 12686819Observational

Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate.

Behnam-Motlagh Parviz, Sandström Per-Erik, Henriksson Roger et al. · J Cancer Res Clin Oncol · 2002

PMID: 12200602ObservationalFull text (PMC)

[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].

Hirayama Yukiyoshi, Ito Yoshihiro, Kanamaru Tomohiro et al. · Gan To Kagaku Ryoho · 2011

PMID: 21403461Case Report

[Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].

Miyake Miki, Nakaigawa Noboru, Kita Kaoru et al. · Hinyokika Kiyo · 2010

PMID: 20104010Case Report

Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient.

Morita Tatsuo · Int Med Case Rep J · 2010

PMID: 23754886Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Estramustine phosphate (substance)
SNOMED CT: 326745006
UMLS CUI: C0356799

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.